Biodesix, in collaboration with Bio-Rad and Thermo Fisher Scientific, is advancing decentralized tumor-informed and tumor-naïve MRD assays designed for clinical labs, with validation underway at Memorial Sloan Kettering Cancer Center.
The DNA-based test showed 96.8% specificity in cervical samples and could help physicians determine which patients need further testing for endometrial cancer.
10x Genomics and Fred Hutchinson Cancer Center have launched a multi-project collaboration to study single cell and spatial profiling for cancer diagnostics, including biomarkers in bladder cancer and residual disease detection in AML.
Project HOPE, funded by The Labcorp Charitable Foundation, has launched a two-year Madison, Wisconsin, initiative with local clinics to expand PSA testing and prostate cancer care for uninsured men facing access barriers.
Read More
Abbott has launched SimpleScreen CRC, an FDA-approved blood test for colorectal cancer screening in average-risk adults, reporting 81.1% sensitivity and 90.4% specificity in a 48,000-patient study.
Read More
An ancillary analysis of the phase III NRG/RTOG 0815 trial shows Veracyte’s Decipher Prostate test can predict which intermediate-risk prostate cancer patients benefit from adding hormone therapy to radiation.
Read More
An FDA advisory panel voted 7-2 that the benefits of GRAIL’s Galleri multi-cancer early detection blood test outweigh its risks for adults 50 and older, supporting its premarket approval application.
Read More
Lucid Diagnostics reports new Medicare, CPT, and ICD-10 panel recommendations supporting reimbursement and coding for its EsoGuard and EsoCheck esophageal cancer tests, advancing billing and clinical tracking pathways.
Read More
A study led by Augusta University found 100% concordance between Nabsys OhmX electronic genome mapping and standard cytogenetic methods in detecting pathogenic variants in AML and CML bone marrow samples.
Read More
A University of Oxford study of 275,000 patients found that tracking trends in 23 routine blood tests over time improved cancer risk prediction in those with unexplained weight loss, compared to single test results.
Read More
bioAffinity Technologies has received a Hong Kong patent for its CyPath Lung diagnostic platform, expanding intellectual property protection for its noninvasive lung cancer detection technology in the Asian market.
Read More
The College of American Pathologists has updated 14 Cancer Protocols, mandating the Breast Phyllodes Tumor protocol for accreditation and revising breast biomarker and GIST molecular testing criteria, according to CAP.
Read More
The investigational PANXEON liquid biopsy detected early-stage pancreatic cancer with 87% sensitivity and low false-positive rates in a multi-center study of nearly 1,800 patients.
Read More
Mayo Clinic researchers report that AI-enabled spatial analysis of standard pathology slides can predict pancreatic cancer recurrence risk more accurately than volume-based methods, according to a study in Clinical Cancer Research.
Read More
CMS has expanded Medicare coverage for non-invasive colorectal cancer screening tests to allow physician associates and advanced practice registered nurses to order assays, including FOBT, according to the American Academy of Physician Associates.
Read More
MolDX has proposed a draft Local Coverage Determination to establish Medicare coverage criteria for optical genome mapping in hematologic neoplasms, with public comment open through Oct. 11, 2026, according to Bionano Laboratories.
Read More
VolitionRx reported 95% detection of early-stage solid cancers in blinded validation of its CTCF-protected ctDNA Capture-Seq liquid biopsy, according to data presented at the ESMO MAP Conference.
Read More
A study from MD Anderson Cancer Center reports that measuring circulating osteoprotegerin may offer a less invasive method to detect and monitor bone metastases in medullary thyroid cancer patients with RET mutations.
Read More